Protocols for Breast Cancer
| HIC 0901004620 Lyndsay Harris M.D. A Randomised, Multi-centre, Open Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer |
| HIC 0609001793 Gina Chung M.D. Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination with Avastin in Hormone Receptor Positive Breast Cancer |
| HIC 0708002990 Gina Chung M.D. A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination with Anastrozole in Patients with Metastatic Breast Cancer |
| HIC 0705002672 Maysa Abu-Khalaf M.D. Q3 week Carboplatin with Weekly Abraxane and Trastuzumab as Neoadjuvant Therapy in Resectable and Unresectable HER2+(Stage IIA-IIIB) Breast Cancer |
| HIC 0601000957 Joanne Weidhaas M.D.;Ph.D. Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I, and II Breast Carcinoma |
| HIC 27735 Joanne Weidhaas M.D.;Ph.D. RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer |
| HIC 0612002137 Lyndsay Harris M.D. A Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination with Irinotecan in Subjects with Advanced Solid Tumors |
| HIC 0803003591 Maysa Abu-Khalaf M.D. A dose-escalating and phase II clinical trial of capecitabine (Xeloda) in combination with the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA, Vorinostat) in advanced breast cancer |
| HIC 0605001396 Maysa Abu-Khalaf M.D. A phase II study of Rapamycin (Rapamune , Sirolimus) and Trastuzumab (Herceptin) for patients with HER-2 receptor positive metastatic breast cancer |
| HIC 0705002671 Maysa Abu-Khalaf M.D. Q3week Carboplatin with Weekly Abraxane and Bevacizumab as Neoadjuvant Therapy in Stage IIA-IIIB HER2-Negative Breast Cancer |